one
major
earliest
mean
recombin
dna
hybridoma
technolog
benefit
mankind
improv
anim
product
reduc
morbid
mortal
infecti
diseas
provid
anim
health
care
industri
efficaci
vaccin
antitoxin
million
cattl
born
last
year
unit
state
approxim
die
infecti
diseas
similarli
million
swine
born
approxim
die
infecti
diseas
loss
occur
despit
use
convent
vaccin
larg
amount
antibiot
medicin
sinc
antibiot
treatment
repres
effect
mean
reduc
sever
diseas
caus
virus
mani
virusinduc
diseas
go
uncheck
either
unavail
appropri
vaccin
avail
ineffect
vaccin
recombin
dna
procedur
enabl
develop
vaccin
virus
grow
poorli
cell
cultur
therefor
present
none
avail
moreov
genet
engin
subunit
vaccin
exhibit
featur
potenc
efficaci
correctli
design
also
safeti
stabil
ambient
temperatur
well
immunolog
geneticallyengin
vaccin
must
develop
fashion
administ
singl
dose
induc
immun
long
durat
must
protect
mani
serotyp
viru
given
geograph
region
possibl
must
induc
advers
reaction
addit
biolog
featur
geneticallyengin
vaccin
exhibit
sever
attract
manufactur
consider
includ
eas
manufactur
economi
product
long
shelf
life
employ
recombin
dna
technolog
gener
larg
amount
viral
surfac
antigen
induc
neutral
antibodi
member
papillomaviru
picornaviru
parvoviru
herpesviru
group
anim
virus
base
upon
preliminari
preclin
clinic
test
sever
geneticallyengin
subunit
vaccin
appar
reagent
excel
immunogen
exhibit
mani
featur
describ
report
present
overal
method
clone
express
surfac
antigen
gene
sever
virus
respons
veterinari
diseas
syndrom
well
data
concern
potenti
use
immunogen
addit
use
recombin
dna
technolog
gener
veterinari
vaccin
also
util
hybridoma
technolog
gener
use
monoclon
antibodi
particular
interest
veterinari
medicin
therapeut
applic
monoclon
antibodi
passiv
immun
certain
infecti
diseas
survey
veterinari
infecti
diseas
identifi
sever
syndrom
treatment
would
best
accomplish
passiv
immun
employ
monoclon
antibodi
one
diseas
syndrom
name
e
coliinduc
neonat
diarrhea
scour
convent
geneticallyengin
vaccin
avail
howev
therapeut
approach
involv
passiv
immun
program
employ
monoclon
antibodi
appear
far
superior
vaccin
prefer
method
prevent
diseas
result
clinic
test
summar
herein
present
detail
elsewher
indic
use
monoclon
antibodi
inde
repres
highli
efficaci
method
curtail
scour
calv
pig
obviat
need
costli
vaccin
program
therebi
eas
burden
manag
farm
anim
scour
form
neonat
diarrhea
calv
swine
caus
enterotoxigen
strain
e
coli
particular
organ
produc
diseas
colon
gut
employ
strain
pilu
antigen
major
adher
factor
found
enterotoxigen
strain
e
coli
subsequ
product
enterotoxin
caus
diarrhea
villou
hypersecret
sinc
colon
consid
essenti
step
pathogenesi
enterotoxigen
colibacillosi
strategi
block
bacteri
adher
small
intestin
passiv
immun
employ
monoclon
antibodi
specif
pilu
antigen
theori
reduc
sever
diseas
sever
previou
studi
fact
lend
support
particular
approach
first
newborn
calv
challeng
strain
e
coli
protect
fatal
diarrhea
permit
ingest
colostrum
cow
previous
vaccin
purifi
pilu
antigen
second
sever
vaccin
trial
use
varieti
piluscontain
prepar
includ
whole
bacterin
crude
extract
also
demonstr
passiv
antibodi
phi
e
coli
would
prevent
sever
fatal
diarrhea
studi
passiv
antibodi
reach
intestin
suckl
calv
colostrum
dam
vaccin
prior
parturit
sever
commerci
vaccin
becom
avail
result
studi
use
appar
success
howev
recogniz
disadvantag
vaccin
first
pregnant
cow
must
handl
vaccin
twice
first
year
subsequ
year
vaccin
program
livestock
owner
reluct
accept
cost
inconveni
prevent
vaccin
unless
recent
experienc
outbreak
neonat
colibacillosi
herd
outbreak
difficult
predict
sinc
epizootiolog
calf
scour
includ
varieti
manag
environment
factor
concern
prompt
investig
altern
method
direct
passiv
immun
newborn
calv
name
oral
administr
monoclon
antibodi
calv
birth
monoclon
antibodi
basic
hybridoma
technolog
use
prepar
monoclon
antibodi
employ
studi
describ
elsewher
balbc
mice
immun
subcutan
inject
purifi
pilu
antigen
complet
freund
adjuv
follow
intraven
booster
shortli
booster
splenic
lymphocyt
isol
fuse
mous
plasmacytoma
figur
immunoprecipit
radiolabel
purifi
pilu
monoclon
antibodi
sever
enterotoxingen
nonpathogen
strain
e
coli
label
smethionin
disrupt
immunoprecipit
monoclon
antibodi
exhibit
agglutin
activ
e
coli
immunoprecipit
pilu
antigen
analyz
polyacrylamid
gel
arrow
indic
posit
pilu
antigen
cell
defici
enzym
hypoxanthin
phosphoribosyl
transferas
result
hybridoma
select
hat
medium
contain
hypoxanthin
aminopterin
thymidin
supernat
hybridoma
screen
antibodi
enzymelink
immunosorb
assay
elisa
use
pilu
antigen
singl
hybridoma
cell
line
produc
larg
amount
monoclon
antibodi
isol
limit
dilut
analysi
screen
elisa
hybridoma
inject
intraperiton
precondit
specif
pathogen
free
balbc
mice
ascit
fluid
collect
day
later
character
monoclon
antibodi
perform
sever
techniqu
includ
elisa
immunoprecipit
agglutin
antibodi
defin
mous
elisa
use
rabbit
isotyp
specif
reagent
antibodi
isol
purifi
ascit
fluid
agglutin
strain
e
coli
dilut
moreov
monoclon
antibodi
appear
groupspecif
sinc
agglutin
differ
subtyp
e
coli
bacteria
grown
instead
c
agglutin
activ
observ
indic
monospecif
pilu
antigen
elabor
lower
incub
temperatur
specif
monoclon
antibodi
pilu
directli
demonstr
immunoprecipit
purifi
pilu
follow
polyacrylamid
gel
electrophoresi
figur
competit
ria
employ
radiolabel
monoclon
antibodi
demonstr
specificreact
reagent
pilu
antigen
clinic
test
monoclon
antibodi
sinc
calv
suscept
e
coli
infect
first
day
life
protocol
treatment
challeng
within
first
hour
age
chosen
order
rigor
test
effect
oral
monoclon
antibodi
deliveri
protect
colibacillosi
oral
administr
monoclon
antibodi
significantli
reduc
mortal
calv
challeng
fatal
dose
enterotoxigen
e
coli
three
clinic
trial
perform
date
sinc
three
trial
carri
differ
locat
employ
differ
protocol
interest
evalu
relationship
calf
surviv
treatment
effect
experiment
locat
protocol
threedimension
analysi
result
three
trial
perform
use
log
linear
regress
three
variabl
evalu
antibodi
administr
calf
surviv
experiment
locat
model
show
calf
surviv
depend
antibodi
administr
independ
experiment
locat
show
best
good
fit
chi
squar
degre
freedom
summari
result
three
trial
shown
tabl
reduct
sever
clinic
symptom
seen
treat
calv
along
reduct
mortal
trial
calv
weigh
period
treat
calv
substanti
lower
weight
loss
untreat
calv
clinic
evalu
period
one
trial
monoclon
antibodi
reduc
mortal
irrespect
given
immedi
e
coli
challeng
sinc
strain
coli
caus
similar
diseas
swine
monoclon
antibodi
test
anim
well
newborn
piglet
treat
antibodi
signific
reduct
mortal
morbid
observ
tabl
pig
howev
two
addit
pathogen
strain
e
coli
found
contribut
diseas
syndrom
strain
attempt
ensur
scour
rigor
control
swine
therefor
gener
monoclon
antibodi
strain
well
addit
monoclon
antibodi
current
undergo
clinic
test
determin
effect
therapeut
reagent
control
diseas
newborn
pig
number
import
veterinari
infecti
diseas
caus
virus
due
unavail
certain
vaccin
poor
efficaci
yet
other
calv
swine
hors
poultri
continu
plagu
infecti
agent
result
either
death
ill
contribut
substanti
loss
farmer
attempt
reduc
loss
employ
recombin
dna
approach
gener
new
effect
vaccin
varieti
virus
includ
member
pap
illomaviru
parvoviru
herpesviru
togaviru
bunyaviru
coronaviru
group
anim
virus
rather
describ
specif
method
clone
assess
rel
potenc
surfac
antigen
speci
describ
overal
gener
method
employ
studi
cite
exampl
sever
differ
group
basic
protocol
develop
geneticallyengin
vaccin
includ
l
identif
major
viral
surfac
antigen
induc
antibodi
capabl
neutral
inactiv
infecti
organ
identif
surfac
antigen
gene
specif
antigen
determin
contain
within
gene
isol
transfer
gene
plasmid
vector
capabl
express
larg
amount
product
ferment
organ
bacteria
yeast
approach
identifi
isol
surfac
antigen
determin
dna
viru
ria
viru
differ
slightli
exampl
locat
surfac
antigen
gene
dna
viru
determin
varieti
method
involv
genet
biochem
approach
one
convent
genet
approach
involv
gener
mutat
viral
genom
analysi
mutant
virus
structur
alter
surfac
antigen
compon
wherea
standard
biochem
approach
involv
either
select
viral
mrna
follow
translat
cellfre
system
determin
specif
mrna
speci
code
surfac
antigen
interest
coupl
vitro
transcriptiontransl
variou
restrict
endonucleas
fragment
viral
dna
pia
virus
viral
genom
gener
revers
transcrib
dna
copi
prior
molecular
clone
instanc
surfac
antigen
gene
isol
step
synthesi
specif
oligonucleotid
repres
sequenc
surfac
antigen
deriv
amino
acid
sequenc
amino
carboxyl
end
surfac
antigen
purifi
viru
capsid
synthet
oligonucleotid
employ
primer
copi
surfac
antigen
gene
dna
enzym
revers
transcriptas
surfac
antigen
gene
splice
plasmid
vector
creat
specif
enabl
express
surfac
antigen
microorgan
e
coli
also
found
creat
gene
fusion
viral
surfac
antigen
gene
certain
prokaryot
eukaryot
gene
appear
offer
distinct
advantag
surfac
antigen
certain
instanc
advantag
includ
stabil
surfac
antigen
gene
product
bacteria
increas
immunogen
surfac
antigen
prohibit
fold
protein
may
otherwis
hide
mask
specif
antigen
determin
requir
gener
neutral
antibodi
possibl
immunolog
enhanc
adjuv
effect
due
presenc
addit
nucleotid
sequenc
adjac
surfac
antigen
gene
fuse
chimer
gene
may
also
actual
help
identifi
bacteria
coloni
express
high
level
surfac
antigen
particularli
fusion
protein
exhibit
enzymat
activ
assay
readili
establish
one
enzym
galactosidas
design
clone
vector
develop
clone
procedur
facilit
identif
bacteria
express
high
level
surfac
antigen
specif
fragment
surfac
antigen
contain
necessari
antigen
determin
requir
neutral
virtu
high
level
galactosidas
activ
present
figur
procedur
ad
featur
elimin
need
locat
isol
surfac
antigen
gene
viru
genom
sinc
enabl
one
f
irst
molecularli
clone
random
fragment
entir
viral
genom
second
select
bacteria
coloni
express
high
level
viral
genebgalactosidas
fusion
protein
final
util
neutral
antibodi
identifi
coloni
produc
antigen
contain
desir
antigen
determin
vector
design
procedur
unabl
express
galactosidas
activ
without
viral
dna
fragment
insert
aminotermin
portion
code
region
clone
site
phase
respect
carboxytermin
portion
clone
site
insert
dna
fragment
proper
number
nucleotid
clone
site
proper
translat
read
phase
amino
termin
portion
allow
translat
carboxytermin
portion
phase
synthesi
hybrid
gene
protein
exhibit
bgalactosidas
activ
clone
identifi
certain
indic
plate
eg
maconkeylactos
xg
screen
product
desir
antigen
determin
use
viralspecif
antiserum
express
viral
surfac
antigen
repres
papillomaviru
picornaviru
parvoviru
herp
viru
group
clone
vector
system
illustr
figur
level
express
e
coli
viral
surfac
antigen
employ
vector
system
rang
total
cellular
protein
certainli
suffici
amount
accommod
product
requir
case
test
surfac
antigen
produc
molecular
clone
react
neutral
antisera
either
polyclon
monoclon
indic
immunoprecipit
viral
surfac
chimer
protein
figur
direct
proof
surfac
antigen
gene
virus
clone
bacteria
inde
encod
protein
contain
requir
antigen
determin
necessari
induc
neutral
antibodi
provid
demonstr
chimer
protein
induc
antibodi
anim
exhibit
capac
neutral
infecti
viru
exampl
antisera
rabbit
inocul
bovin
papillomaviru
chimer
protein
specif
inactiv
bpvinduc
transform
cell
cultur
figur
level
neutral
antibodi
gener
chimer
surfac
antigen
protein
high
indic
reagent
serv
effect
immunogen
tabl
asera
rabbit
b
test
viru
neutral
presenc
complement
heat
inactiv
c
minut
complement
activ
guinea
pig
complement
complement
serum
dilut
gave
plaqu
reduct
compar
preimmun
serum
control
indic
util
recombin
dna
hybridoma
technolog
attempt
develop
efficaci
veterinari
vaccin
antitoxin
direct
reduc
morbid
mortal
infecti
diseas
end
develop
varieti
monoclon
antibodi
vaccin
technolog
either
complet
process
complet
clinic
field
trial
reagent
analysi
reagent
date
appear
advanc
gene
technolog
clearli
effect
anim
veterinari
health
care
industri
first
product
reach
marketplac
monoclon
antibodi
reagent
effect
significantli
reduc
morbid
mortal
due
enterotoxigen
strain
e
coli
clinic
studi
date
administ
oral
skim
milk
colostrum
fed
colostrumdepriv
calv
result
studi
indic
monoclon
antibodi
direct
pilu
significantli
reduc
mortal
newborn
calv
challeng
fatal
dose
strain
e
coli
reduc
mortal
explain
result
monoclon
antibodi
inhibit
colon
intestin
strain
e
coli
antibodi
direct
capsular
somat
antigen
e
coli
appear
involv
reduc
mortal
occurr
enterotoxigen
colibacillosi
calv
often
sporat
depend
interact
factor
colostrum
ingest
weather
chang
stock
rate
sinc
incid
diseas
low
year
may
hard
convinc
livestock
owner
vaccin
cow
prevent
scour
cost
effect
outbreak
neonat
diarrhea
subsequ
occur
gener
late
vaccin
cow
passiv
protect
offspr
oral
administr
monoclon
antibodi
calv
birth
may
effect
way
reduc
econom
loss
farmer
outbreak
confirm
scour
occur
herd
cow
previous
vaccin
novel
form
therapi
calf
scour
obviat
need
vaccin
therefor
provid
much
better
approach
reduc
spread
scour
also
benefit
farmer
financi
well
first
clinic
use
monoclon
antibodi
passiv
immun
veterinari
medicin
novel
veterinari
vaccin
also
develop
geneticengin
approach
report
describ
overal
method
clone
express
high
level
surfac
antigen
gene
varieti
virus
respons
variou
diseas
syndrom
bovin
swine
importantli
abl
demonstr
surfac
antigen
produc
bacteria
approach
exhibit
capac
induc
antibodi
anim
neutral
activ
live
infecti
viru
preclin
clinic
trial
date
level
neutral
antibodi
induc
similar
better
level
protect
antibodi
present
anim
recov
diseas
receiv
viral
vaccin
pend
result
rigor
clinic
trial
present
ongo
reagent
appear
repres
econom
mean
farmer
cattlemen
hors
rancher
abl
reduc
morbid
mortal
infecti
diseas
affect
respiratori
alimentari
urogenit
tract
varieti
econom
import
anim
speci
expect
sell
price
lower
vaccin
current
market
also
expect
monoclon
anitbodi
better
valu
farmer
cow
vaccin
far
product
concern
abl
adapt
cell
clutur
procedur
equal
product
cost
mice
initi
product
carri
mice
j
nunberg
beef
dairi
practic
calv
occur
rang
barn
determin
whether
farmer
abl
deliv
monoclon
antibodi
within
first
day
life
aj
fara
vast
major
calv
dairi
oper
occur
confin
moreov
mani
beef
calv
also
access
handl
one
day
age
least
beef
calv
born
herd
cow
less
thu
farmer
awar
health
problem
easi
access
newborn
calv
p
kung
clinic
trial
inject
newborn
anim
strain
test
real
test
lie
field
random
trial
trial
complet
j
fara
field
random
trial
complet
canada
current
progress
unit
state
sinc
data
assimil
unabl
present
canadian
larg
scale
field
trial
success
death
due
scour
newborn
calv
administ
product
occur
fact
result
field
trial
facilit
govern
licens
first
commerci
order
product
sale
canada
mcnab
monoclon
igg
molecul
would
advantag
stabilitywis
iga
aj
fara
minim
amount
proteas
newborn
calf
gut
moreov
view
efficaci
pursu
either
prepar
test
type
monoclon
igg
suffici
effect
reduc
incid
diseas
clinic
field
trial
duri
ng
critic
hour
period
follow
calv
problem
associ
antibodi
hand
cours
would
look
altern
cab
abl
observ
express
parvoviru
capsid
protein
bacteria
j
fara
clone
express
larg
open
read
frame
describ
earlier
morn
l
arg
open
read
frame
contain
sequenc
code
three
overlap
capsid
peptid
protein
gener
bacteria
code
region
porcin
parvoviru
genom
induc
neutral
anti
bodi
anim
gelfand
indic
one
advantag
monoclon
antibodi
farmer
could
shelf
encount
problem
could
use
could
monoclon
antibodi
given
exposur
diseas
aj
fara
clinic
trial
administ
anim
expos
diseas
want
ensur
calf
expos
diseas
yet
farmer
could
give
antibodi
anim
prevent
onset
infect
obvious
want
set
object
mind
gelfand
short
time
exposur
administ
antibodi
aj
fara
data
indic
within
first
coupl
hour
oral
administ
antibodi
effect
prevent
diseas
develop
gelfand
farmer
realli
still
need
immun
everi
calf
j
fara
farmer
need
administ
product
anim
deem
risk
suffici
valu
warrant
protect
gelfand
know
problem
j
fara
one
calf
come
diseas
simpli
oral
administ
antibodi
anim
might
expos
joseph
instead
use
antibodi
protect
cow
feed
e
col
anim
popul
gut
oral
antibodi
provid
instant
protect
follow
administr
suppli
nonpathogen
strain
popul
gut
would
provid
rapid
protect
n
steb
e
col
strain
would
job
elicit
respons
pathogen
j
fara
would
probabl
remov
pl
asmid
produc
enterotoxin
popul
gut
bacteria
howev
direct
data
indic
type
therapi
would
work
joseph
state
gut
popul
normal
bacteria
problem
j
fara
current
percept
happen
